MedTrace Logo

Use of Angiotensin-(1-7) in COVID-19

NCT04633772 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2021-11-09

No results posted yet for this study

Summary

The renin-angiotensin system (RAS) has a relevant role in COVID-19, as the virus will enter host's cells via the angiotensin-converting enzyme 2 (ACE2); RAS disequilibrium might also play a key role in the modulation of the inflammatory response that characterizes the lung involvement. Angiotensin-(1-7) is a peptide that could be altered in COVID-19 patient and its supplementation may potentially helpful in this setting.

Conditions

Interventions

DRUG

Angiotensin-(1-7)

Intravenous supplementation of Angiotensin-(1-7)

DRUG

Placebo

NaCl 0.9%

Sponsors & Collaborators

  • Federal University of Minas Gerais

    collaborator OTHER

  • Angitec

    collaborator UNKNOWN

  • Fonds Erasme pour la Recherche Medicale

    collaborator UNKNOWN

  • Erasme University Hospital

    lead OTHER

Principal Investigators

  • Robson AS Santos · Angitex

  • Ana Martins Valle · Federal University of Minas Gerais

  • Filippo Annoni · H.U.B Erasme

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
17 Years
Max Age
81 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-05
Primary Completion
2021-11-01
Completion
2021-11-01

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04633772 on ClinicalTrials.gov